{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125336","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.536516+00:00","generated_at":"2026-05-30T02:05:00.807045+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Climb Bio Q3 net loss $8.9M; cash $217.9M through 2027; FDA IND cleared for SLE trial","bullets":["Net loss $8.9M for Q3 2024 vs $4.0M Q3 2023; R&D expenses $6.2M, G&A $5.5M.","Cash $217.9M as of Sep 30, 2024; expected to fund operations through 2027.","FDA cleared IND for budoprutug in SLE; Phase 1b trial planned H1 2025.","Appointed Doug Williams as Chair of Board; Gary Hao as VP of CMC.","Phase 1b pMN data showed 60% complete remission; Phase 2 ITP trial planned H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125336","json":"https://secwatch.observer/filing/0000950170-24-125336.json","markdown":"https://secwatch.observer/filing/0000950170-24-125336.md","text":"https://secwatch.observer/filing/0000950170-24-125336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/0000950170-24-125336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017024125336/clym-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:05:00.807045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}